Prognostic Impact of Circulating Tumor Plasma Cells in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
J. Clin. Oncol 2022 Sep 20;40(27)3120-3131, L Bertamini, S Oliva, D Rota-Scalabrini, L Paris, S Morè, P Corradini, A Ledda, M Gentile, G De Sabbata, G Pietrantuono, A Pascarella, P Tosi, P Curci, M Gilestro, A Capra, P Galieni, F Pisani, O Annibali, F Monaco, AM Liberati, S Palmieri, M Luppi, R Zambello, F Fazio, A Belotti, P Tacchetti, P Musto, M Boccadoro, F GayFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.